Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
- Posted on August 11, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Generating AI summary…
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz's pipeline and presence in rare epilepsy treatments.
